Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
1.240
0.00 (0.00%)
May 9, 2025, 10:51 AM - Market open
Inozyme Pharma Stock Forecast
INZY's stock price has decreased by -73.28% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Inozyme Pharma stock have an average target of 17.22, with a low estimate of 11 and a high estimate of 30. The average target predicts an increase of 1,288.71% from the current stock price of 1.24.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Inozyme Pharma stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 2 | 2 | 3 | 3 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +1,190.32% | Apr 10, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,109.68% | Apr 8, 2025 |
| Raymond James | Raymond James | Buy Maintains $24 → $12 | Buy | Maintains | $24 → $12 | +867.74% | Mar 12, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $30 → $23 | Buy | Maintains | $30 → $23 | +1,754.84% | Mar 11, 2025 |
| Needham | Needham | Strong Buy Maintains $23 → $15 | Strong Buy | Maintains | $23 → $15 | +1,109.68% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
n/a
from 295.70M
Revenue Next Year
n/a
EPS This Year
-1.41
from -1.62
EPS Next Year
-1.21
from -1.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 39.2M | 131.1M | ||
| Avg | n/a | 5.4M | 36.2M | ||
| Low | n/a | n/a | 2.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 2,331.3% | ||
| Avg | - | - | 570.4% | ||
| Low | - | - | -45.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.09 | -0.38 | -0.41 | ||
| Avg | -1.41 | -1.21 | -1.28 | ||
| Low | -1.72 | -1.55 | -2.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.